NCT02250222View on ClinicalTrials.gov

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

LGD-6972

LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)

DRUG

Placebo (Captisol ®)

betadex \[β-cyclodextrin\] sulfobutylether sodium, NF

Trial Locations (3)

33014

Clinical Pharmacology of Miami, Inc, Miami

45227

Medpace Clinical Pharmacology, Cincinnati

85283

Celerion, Inc, Tempe

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY